Coronavirus Update: Japan's Supercomputer Joins COVID-19 Drug Hunt
Plus: WHO Drops Hydroxychloroquine Trial
Developed by Japan’s national research institute, the supercomputer has been tasked with characterizing the SARS-CoV-2 virus, identifying therapeutic molecules, modeling infection spread and socio-economic impact.
You may also be interested in...
Sotrovimab data could help with uptake, though the market remains challenging as infections fall. Plus RedHill presents encouraging Phase II data for oral drug to treat COVID-19 infection and inflammation after completing Phase II/III study enrollment and Japan taps its world-leading supercomputer.
A study presented at a recent MIT-sponsored conference used network medicine to uncover dozens of potential opportunities for existing drugs to be repurposed for COVID-19.
The WHO’s “Solidarity” trial investigators have decided to interrupt the trials with immediate effect since the clinical trial found that hydroxychloroquine and lopinavir/ritonavir “produced little or no reduction in the mortality of the hospitalized COVID-19 patients.”